Halozyme Therapeutics, Inc.
IT ˙ BIT ˙ US40637H1095
58,52 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1HALO / Halozyme Therapeutics, Inc.
InstitutionCreative Planning
Latest Disclosed Ownership54,236 shares
Latest Disclosed Value $ 3,505,273
Creative Planning ownership in 1HALO / Halozyme Therapeutics, Inc.

On May 12, 2026 - Creative Planning filed a 13F-HR form disclosing ownership of 54,236 shares of Halozyme Therapeutics, Inc. (IT:1HALO) valued at $2,927,659 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 51,018 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 6.31% during the quarter. The current value of the position is $3,173,891 USD.

Creative Planning has a history of taking positions in derivatives of the underlying security (1HALO) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1HALO / Halozyme Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 54,236 3,218 6.31 3,505 2.10 0.0023
2026-02-17 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 51,018 -4,276 -7.73 3,434 -15.34 0.0025
2025-11-14 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 55,294 4,668 9.22 4,055 54.01 0.0031
2025-08-08 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 50,626 -14,890 -22.73 2,634 -37.01 0.0022
2025-05-15 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 65,516 20,002 43.95 4,181 92.10 0.0039
2025-02-14 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 45,514 -1,320 -2.82 2,176 -18.81 0.0021
2024-10-11 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 46,834 9,543 25.59 2,681 37.30 0.0027
2024-08-15 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 37,291 11,249 43.20 1,953 84.32 0.0021
2024-05-13 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 26,042 4,508 20.93 1,059 33.21 0.0012
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 21,534 4,753 28.32 796 24.02 0.0015
2023-11-16 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 16,781 3,311 24.58 641 32.16 0.0009
2023-07-21 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,470 13,470 486 0.0006
2023-05-15 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -4,824 -100.00 0 -100.00
2023-02-10 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 4,824 4,824 274 0.0004
2020-05-05 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -10,692 -100.00 0 -100.00
2020-01-30 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 10,692 -23,000 -68.27 190 -63.67 0.0006
2019-11-01 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 33,692 0 0.00 523 -9.67 0.0017
2019-07-26 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 33,692 -5,000 -12.92 579 -7.06 0.0019
2019-04-24 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 38,692 -24,500 -38.77 623 -32.58 0.0022
2019-02-12 2018-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 63,192 -600 -0.94 924 -20.28 0.0038
2019-02-01 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 63,192 -600 924
2018-10-25 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 63,792 -10,000 -13.55 1,159 -6.91 0.0043
2018-07-20 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 73,792 -11,000 -12.97 1,245 -25.05 0.0049
2018-04-18 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 84,792 -2,890 -3.30 1,661 -6.48 0.0068
2018-01-17 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 87,682 -1,410 -1.58 1,776 14.73 0.0077
2017-10-17 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 89,092 -25,575 -22.30 1,548 5.31 0.0072
2017-07-12 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 114,667 1,383 1.22 1,470 0.14 0.0074
2017-04-07 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 113,284 7,534 7.12 1,468 40.48 0.0080
2017-01-09 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 105,750 2,500 2.42 1,045 -16.20 0.0064
2016-10-12 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 103,250 -34,100 -24.83 1,247 5.23 0.0079
2016-07-12 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 137,350 -15,000 -9.85 1,185 -17.88 0.0086
2016-04-08 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 152,350 16,000 11.73 1,443 -38.93 0.0113
2016-01-11 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 136,350 8,000 6.23 2,363 37.06 0.0194
2015-10-09 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 128,350 8,000 6.65 1,724 -36.57 0.0152
2015-07-09 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 120,350 89,250 286.98 2,718 512.16 0.0247
2015-04-13 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 31,100 31,100 0.00 444 0.0042
2015-01-29 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -61,600 -100.00 0 -100.00
2014-10-10 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 61,600 800 1.32 561 -6.66 0.0065
2014-08-20 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 60,800 1,200 2.01 601 -20.61 0.0078
2014-04-11 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 59,600 -300 -0.50 757 -15.70 0.0114
2014-01-06 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 59,900 29,100 94.48 898 164.12 0.0153
2013-10-10 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 30,800 0 0.00 340 38.78 0.0067
2013-07-09 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 30,800 30,800 245 0.0057
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-04-07 2017-03-31 13F HALOZYME THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2017-01-09 2016-12-31 13F HALOZYME THERAPEUTICS COM Call 30,000 0.00 2 -66.67 n/a n/a n/a
2016-10-12 2016-09-30 13F HALOZYME THERAPEUTICS COM Call 30,000 0.00 6 50.00 n/a n/a n/a
2016-07-12 2016-06-30 13F HALOZYME THERAPEUTICS COM Call 30,000 0.00 4 -50.00 n/a n/a n/a
2016-04-08 2016-03-31 13F HALOZYME THERAPEUTICS COM Call 30,000 -25.00 8 -95.53 n/a n/a n/a
2016-01-11 2015-12-31 13F HALOZYME THERAPEUTICS COM Call 40,000 0.00 179 65.74 n/a n/a n/a
2015-10-09 2015-09-30 13F HALOZYME THERAPEUTICS COM Call 40,000 100.00 108 -50.00 n/a n/a n/a
2015-07-09 2015-06-30 13F HALOZYME THERAPEUTICS COM Call 20,000 216 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.